MKI67 and neoplasm: Recently, the phase I MIPRA trial exploring the effects of mifepristone in women with breast cancer pre-selected for high PR-A:PR-B ratios in the tumor demonstrated a significant decrease in Ki-67 proliferation marker with an increase in Cleaved caspase 3 compared to baseline expression after two weeks of treatment (119).